title: Measurement of oxidized lipoprotein (a) in patients with acute coronary syndromes and stable coronary artery disease by 2 ELISAs: using different capture antibody against oxidized lipoprotein (a) or oxidized LDL.
abstract: OBJECTIVE
  To evaluate clinical value of oxidized lipoprotein(a) [ox-Lp(a)] levels.
  
  
  METHODS
  Ox-Lp(a) were measured by 2 ELISAs using antibodies against ox-Lp(a) [ox-Lp(a)1] or oxidized low-density lipoprotein [ox-Lp(a)2], and studied in 161 acute coronary syndromes (ACS) patients, 114 stable coronary artery disease (CAD) and 100 control subjects.
  
  
  RESULTS
  Ox-Lp(a)1 was found related with ox-Lp(a)2 (r=0.864, P=0.000). Controlling for plasma lipids, Lp(a) and clinical characteristics, odds ratios of ox-Lp(a)1 on ACS and stable CAD were 5.06 (95% confidence interval 1.82-14.04) and 2.20 (0.78-6.22); those of ox-Lp(a)2 were 3.37 (1.07-10.63) and 1.35 (0.41-4.48), respectively. Receiver-operating characteristic curve analysis confirmed that performances of ox-Lp(a)1 were significantly superior to those for ox-Lp(a)2 in ACS (area: 0.803 vs. 0.723, P<0.001) and stable CAD (area: 0.670 vs. 0.607, P<0.01).
  
  
  CONCLUSIONS
  Ox-Lp(a) levels using antibodies against ox-Lp(a) may represent a better risk marker than those using antibodies against oxidized low-density lipoprotein for ACS and stable CAD.
authors.affiliation: Department of Biochemistry, Jinling Hospital, Clinical School of Medicine, Nanjing University, Nanjing 210002, PR China.
authors.forename: Jun-jun
authors.initials: JJ
authors.lastname: Wang
authors.forename: Ai-zhong
authors.initials: AZ
authors.lastname: Han
authors.forename: Yang
authors.initials: Y
authors.lastname: Meng
authors.forename: Jian-bin
authors.initials: JB
authors.lastname: Gong
authors.forename: Chun-ni
authors.initials: CN
authors.lastname: Zhang
authors.forename: Ke
authors.initials: K
authors.lastname: Li
authors.forename: Yu-Xiu
authors.initials: YX
authors.lastname: Liu
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood* / Q000175:diagnosis / Q000378:metabolism; D000368:Aged; D000906:Antibodies / Q000494:pharmacology*; D016022:Case-Control Studies; D003324:Coronary Artery Disease / Q000097:blood* / Q000175:diagnosis / Q000378:metabolism; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D017270:Lipoprotein(a) / Q000032:analysis* / Q000097:blood / Q000276:immunology* / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000032:analysis / Q000097:blood / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D011237:Predictive Value of Tests; D012372:ROC Curve; D012720:Severity of Illness Index
chemical_list: D000906:Antibodies; D017270:Lipoprotein(a); D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein